A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Study sponsor: Tonix Pharmaceuticals, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-02Estimated
Enrollment · participants360Estimated
Source updated2026-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.